Get the Stockscreener App
9.76
2.41%
0.23
After Hours:
10.48
0.72
+7.38%
Atara Biotherapeutics Inc stock is traded at $9.76, with a volume of 132.73K.
It is up +2.41% in the last 24 hours and up +11.29% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
See More
Previous Close:
$9.53
Open:
$9.45
24h Volume:
132.73K
Relative Volume:
1.96
Market Cap:
$97.97M
Revenue:
$23.14M
Net Income/Loss:
$-9.47M
P/E Ratio:
-11.06
EPS:
-0.8827
Net Cash Flow:
$-25.88M
1W Performance:
+6.09%
1M Performance:
+11.29%
6M Performance:
+81.08%
1Y Performance:
-23.75%
1-Day Range:
$9.25
$9.95
1-Week Range:
$8.80
$9.95
52-Week Range:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
9.76 | 94.15M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Independent Director of Atara Biotherapeutics Picks Up 272% More Stock - simplywall.st
Atara Biotherapeutics (ATRA) Director Brian Cherry Buys 104,166 Shares - GuruFocus
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Canada
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares By Investing.com - Investing.com South Africa
Atara Biotherapeutics Director Purchased Shares Worth Over $999K - TradingView
(ATRA) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review
Atara Biotherapeutics director Brian Cherry acquires 104,166 common shares for $999,993.60 - Bitget
Atara Biotherapeutics president and CEO sells $40,882 in shares By Investing.com - Investing.com Nigeria
Atara Biotherapeutics president and CEO sells $40,882 in shares - Investing.com India
Atara Biotherapeutics (ATRA) employee plans 5,062-share tax sale - Stock Titan
Atara (ATRA) Results Breakdown: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report Move: The Stock Records a 1.26% Increase at the CloseProfit Growth Outlook - vinanet.vn
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan
Atara Biotherapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ATRA | US0465132068 - marketscreener.com
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade
Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus
Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat
Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView
Atara Biotherapeutics: Q2 Earnings Snapshot - AOL.com
BRIEF-Atara Biotherapeutics Q2 EPS USD -0.32 - TradingView
Atara Biotherapeutics (ATRA) Rallies 3.8% to $8.94, Approaching Resistance at $9.39Volume Nodes - dars.gov.et
Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline? - Kalkine Media
ATRA DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a shareEarnings Preview - TradingView
ATRA Q2'26 Earnings: EPS estimate is (0.32) USD - TradingView
ATRA DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Understanding Momentum Shifts in (ATRA) - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ATRA Q2'26 Earnings: revenue estimate is 550.00K USD - TradingView
Atara Biotherapeutics (ATRA) Projected to Release Earnings on Monday - MarketBeat
Enterprise value to revenue forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA - TradingView
Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EcoR1 Capital LLC Sells 473,590 Shares of Atara Biotherapeutics, Inc. $ATRA - MarketBeat
Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Form 13D/A Atara Biotherapeutics For: 24 July By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc (ATRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Form 4 Atara Biotherapeutics Inc For: 24 July By Investing.com - Investing.com Nigeria
Atara Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ATRA - TradingView
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):